Z Stelmasiak

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex^®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Alena Novotná, Jan Mareš, S. Ratcliffe et al. · European Journal of Neurology · 2011 · 464 citations

Medicine, Neurology, Pharmacology +17

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

A Double-Blind Randomised Placebo-Controlled Evaluation of Three Doses of Botulinum Toxin Type A (Dysport<sup>®</sup>) in the Treatment of Spastic Equinovarus Deformity after Stroke

Sean J. Pittock, A. P. Moore, Orla Hardiman et al. · Cerebrovascular Diseases · 2003 · 201 citations

Medicine, Neurology, Rehabilitation Medicine +17

Long-term safety and efficacy of teriflunomide

Paul O’Connor, Mark S. Freedman, Aaron Miller et al. · Neurology · 2016 · 126 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease

Halina Bartosik-Psujek, Z Stelmasiak · European Journal of Neurology · 2004 · 101 citations

Life Sciences, Clinical Sciences, Immunology +17